Adverum Biotechnologies (ADVM)
(Real Time Quote from BATS)
$7.80 USD
+0.15 (1.96%)
Updated Oct 14, 2024 01:08 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Income Statements
Fiscal Year end for Adverum Biotechnologies, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 4 | 0 | 8 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 4 | 0 | 8 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 128 | 157 | 154 | 118 | 69 |
Income After Depreciation & Amortization | -124 | -157 | -146 | -118 | -69 |
Non-Operating Income | 6 | 3 | 1 | 2 | 4 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -118 | -154 | -146 | -116 | -64 |
Income Taxes | -1 | 0 | 0 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -117 | -155 | -146 | -118 | -64 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -117 | -155 | -146 | -118 | -64 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -120 | -147 | -139 | -112 | -66 |
Depreciation & Amortization (Cash Flow) | 4 | 10 | 7 | 6 | 2 |
Income After Depreciation & Amortization | -124 | -157 | -146 | -118 | -69 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 10.08 | 9.93 | 9.80 | 8.52 | 6.41 |
Diluted EPS Before Non-Recurring Items | -11.60 | -15.60 | -14.80 | -13.80 | -10.10 |
Diluted Net EPS (GAAP) | -11.60 | -15.60 | -14.80 | -13.80 | -10.10 |
Fiscal Year end for Adverum Biotechnologies, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 20.89 | 26.84 | 26.16 | 34.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -20.89 | -26.84 | -26.16 | -34.53 |
Non-Operating Income | NA | 2.41 | 2.05 | 1.31 | 1.66 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -18.48 | -24.79 | -24.85 | -32.87 |
Income Taxes | NA | 0.00 | 0.00 | -1.13 | 0.02 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -18.48 | -24.79 | -23.71 | -32.89 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -18.48 | -24.79 | -23.71 | -32.89 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 20.85 | 16.48 | 10.12 | 10.10 |
Diluted EPS Before Non-Recurring Items | NA | -0.89 | -1.50 | -2.30 | -3.30 |
Diluted Net EPS (GAAP) | NA | -0.89 | -1.50 | -2.30 | -3.30 |